{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T11:21:14Z","timestamp":1794568874119,"version":"4.9.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100012051","name":"Lupus Research Alliance","doi-asserted-by":"publisher","award":["Empowering Lupus Research Supplement Award"],"award-info":[{"award-number":["Empowering Lupus Research Supplement Award"]}],"id":[{"id":"10.13039\/100012051","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012051","name":"Lupus Research Alliance","doi-asserted-by":"publisher","award":["Target Identification in Lupus Award"],"award-info":[{"award-number":["Target Identification in Lupus Award"]}],"id":[{"id":"10.13039\/100012051","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001582","name":"Dermatology Foundation","doi-asserted-by":"publisher","award":["Women\u2019s Health Career Development Award"],"award-info":[{"award-number":["Women\u2019s Health Career Development Award"]}],"id":[{"id":"10.13039\/100001582","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-60937-5","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T06:05:28Z","timestamp":1784700328000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Spatial characterization of interface dermatitis in cutaneous lupus reveals novel chemokine axis-mediated recruitment of leukocytes that drive disease"],"prefix":"10.1038","volume":"16","author":[{"given":"Saeed","family":"Shakiba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazgol-Sadat","family":"Haddadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khashayar","family":"Afshari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet E.","family":"Lubov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haya S.","family":"Raef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00dcmm\u00fcg\u00fcls\u00fcm","family":"Yildiz-Altay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mridushi","family":"Daga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggi Ahmed","family":"Refat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangeline","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna Galindo","family":"de Laflin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andressa","family":"Akabane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Vongvirath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shany","family":"Sherman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James P.","family":"Strassner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Leon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina E.","family":"Baer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Dresser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James B.","family":"Whitley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sladjana","family":"Skopelja-Gardner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John E.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Vesely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Rashighi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jillian M.","family":"Richmond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"60937_CR1","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.3389\/fimmu.2020.01353","volume":"11","author":"CJ Garelli","year":"2020","unstructured":"Garelli, C. J. et al. Current insights in cutaneous lupus erythematosus immunopathogenesis. Front. Immunol. 11, 1353 (2020).","journal-title":"Front. Immunol."},{"key":"60937_CR2","doi-asserted-by":"crossref","unstructured":"Schultz, H. Y. et al. From pathogenesis, epidemiology, and genetics to definitions, diagnosis, and treatments of cutaneous lupus erythematosus and dermatomyositis: a report from the 3rd International Conference on Cutaneous Lupus Erythematosus (ICCLE) 2013. J. Invest. Dermatol. 135, 7\u201312 (2015).","DOI":"10.1038\/jid.2014.316"},{"key":"60937_CR3","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1177\/0961203316628997","volume":"25","author":"A Reich","year":"2016","unstructured":"Reich, A. et al. Treatment of cutaneous lupus erythematosus: current practice variations. Lupus 25, 964\u2013972 (2016).","journal-title":"Lupus"},{"key":"60937_CR4","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1007\/s11926-011-0180-z","volume":"13","author":"AY Chang","year":"2011","unstructured":"Chang, A. Y. & Werth, V. P. Treatment of cutaneous lupus. Curr. Rheumatol. Rep. 13, 300\u2013307 (2011).","journal-title":"Curr. Rheumatol. Rep."},{"key":"60937_CR5","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1097\/BOR.0000000000000308","volume":"28","author":"JN Stannard","year":"2016","unstructured":"Stannard, J. N. & Kahlenberg, J. M. Cutaneous lupus erythematosus: updates on pathogenesis and associations with systemic lupus. Curr. Opin. Rheumatol. 28, 453\u2013459 (2016).","journal-title":"Curr. Opin. Rheumatol."},{"key":"60937_CR6","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1111\/j.1365-2133.2007.08137.x","volume":"157","author":"J Wenzel","year":"2007","unstructured":"Wenzel, J. et al. The expression pattern of interferon-inducible proteins reflects the characteristic histological distribution of infiltrating immune cells in different cutaneous lupus erythematosus subsets. Br. J. Dermatol. 157, 752\u2013757 (2007).","journal-title":"Br. J. Dermatol."},{"key":"60937_CR7","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1111\/j.0022-202X.2005.23755.x","volume":"124","author":"J Wenzel","year":"2005","unstructured":"Wenzel, J. et al. Role of the chemokine receptor CCR4 and its ligand thymus- and activation-regulated chemokine\/CCL17 for lymphocyte recruitment in cutaneous lupus erythematosus. J. Invest. Dermatol. 124, 1241\u20131248 (2005).","journal-title":"J. Invest. Dermatol."},{"key":"60937_CR8","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.cyto.2019.03.010","volume":"119","author":"S M\u00e9ndez-Flores","year":"2019","unstructured":"M\u00e9ndez-Flores, S. et al. Inflammatory chemokine profiles and their correlations with effector CD4 T cell and regulatory cell subpopulations in cutaneous lupus erythematosus. Cytokine 119, 95\u2013112 (2019).","journal-title":"Cytokine"},{"key":"60937_CR9","doi-asserted-by":"crossref","unstructured":"Berthier, C. C. et al. Molecular profiling of cutaneous lupus lesions identifies subgroups distinct from clinical phenotypes. J. Clin. Med. Res. 8, 859 (2019).","DOI":"10.3390\/jcm8081244"},{"key":"60937_CR10","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.jaad.2016.12.021","volume":"76","author":"JP Strassner","year":"2017","unstructured":"Strassner, J. P., Rashighi, M., Ahmed Refat, M., Richmond, J. M. & Harris, J. E. Suction blistering the lesional skin of vitiligo patients reveals useful biomarkers of disease activity. J. Am. Acad. Dermatol. 76, 847\u2013855e5 (2017).","journal-title":"J. Am. Acad. Dermatol."},{"key":"60937_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2024.02.020","author":"I Doleckova","year":"2024","unstructured":"Doleckova, I. et al. Calpain inhibition protects against UVB-induced degradation of dermal-epidermal junction-associated proteins. J. Invest. Dermatol. https:\/\/doi.org\/10.1016\/j.jid.2024.02.020 (2024).","journal-title":"J. Invest. Dermatol."},{"key":"60937_CR12","doi-asserted-by":"publisher","first-page":"eabj3289","DOI":"10.1126\/scitranslmed.abj3289","volume":"15","author":"S Lavazais","year":"2023","unstructured":"Lavazais, S. et al. IRAK4 inhibition dampens pathogenic processes driving inflammatory skin diseases. Sci. Transl Med. 15, eabj3289 (2023).","journal-title":"Sci. Transl Med."},{"key":"60937_CR13","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1038\/cdd.2012.51","volume":"19","author":"R Pierini","year":"2012","unstructured":"Pierini, R. et al. AIM2\/ASC triggers caspase-8-dependent apoptosis in Francisella-infected caspase-1-deficient macrophages. Cell. Death Differ. 19, 1709\u20131721 (2012).","journal-title":"Cell. Death Differ."},{"key":"60937_CR14","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/cmi.2016.35","volume":"14","author":"RA Ratsimandresy","year":"2016","unstructured":"Ratsimandresy, R. A., Indramohan, M., Dorfleutner, A. & Stehlik, C. The AIM2 inflammasome is a central regulator of intestinal homeostasis through the IL-18\/IL-22\/STAT3 pathway. Cell. Mol. Immunol. 14, 127\u2013142 (2016).","journal-title":"Cell. Mol. Immunol."},{"key":"60937_CR15","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1093\/intimm\/dxl021","volume":"18","author":"Y Ishikawa","year":"2006","unstructured":"Ishikawa, Y., Yoshimoto, T. & Nakanishi, K. Contribution of IL-18-induced innate T cell activation to airway inflammation with mucus hypersecretion and airway hyperresponsiveness. Int. Immunol. 18, 847\u2013855 (2006).","journal-title":"Int. Immunol."},{"key":"60937_CR16","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1002\/eji.200838660","volume":"39","author":"S Struyf","year":"2009","unstructured":"Struyf, S. et al. Synergistic up-regulation of MCP-2\/CCL8 activity is counteracted by chemokine cleavage, limiting its inflammatory and anti-tumoral effects. Eur. J. Immunol. 39, 843\u2013857 (2009).","journal-title":"Eur. J. Immunol."},{"key":"60937_CR17","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1002\/art.38573","volume":"66","author":"ME Munroe","year":"2014","unstructured":"Munroe, M. E. et al. Proinflammatory adaptive cytokine and shed tumor necrosis factor receptor levels are elevated preceding systemic lupus erythematosus disease flare. Arthritis rheumatol. 66, 1888\u20131899 (2014).","journal-title":"Arthritis rheumatol."},{"key":"60937_CR18","doi-asserted-by":"crossref","unstructured":"Skopelja-Gardner, S., An, J., Tai, J., Tanaka, L. & Sun, X. The early local and systemic Type I interferon responses to ultraviolet B light exposure are cGAS dependent. Sci. Rep. (2020).","DOI":"10.1101\/835132"},{"key":"60937_CR19","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s12026-012-8297-3","volume":"53","author":"KL Wong","year":"2012","unstructured":"Wong, K. L. et al. The three human monocyte subsets: implications for health and disease. Immunol. Res. 53, 41\u201357 (2012).","journal-title":"Immunol. Res."},{"key":"60937_CR20","doi-asserted-by":"publisher","first-page":"eabn2263","DOI":"10.1126\/scitranslmed.abn2263","volume":"14","author":"AC Billi","year":"2022","unstructured":"Billi, A. C. et al. Nonlesional lupus skin contributes to inflammatory education of myeloid cells and primes for cutaneous inflammation. Sci. Transl Med. 14, eabn2263 (2022).","journal-title":"Sci. Transl Med."},{"key":"60937_CR21","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/01.LAB.0000048719.53282.00","volume":"83","author":"A Wuyts","year":"2003","unstructured":"Wuyts, A. et al. The CXC chemokine GCP-2\/CXCL6 is predominantly induced in mesenchymal cells by interleukin-1\u03b2 and is down-regulated by interferon-\u03b3: comparison with interleukin-8\/CXCL8. Lab. Invest. 83, 23\u201334 (2003).","journal-title":"Lab. Invest."},{"key":"60937_CR22","doi-asserted-by":"publisher","first-page":"5586","DOI":"10.4049\/jimmunol.1301319","volume":"192","author":"A Rodriguez-Pla","year":"2014","unstructured":"Rodriguez-Pla, A. et al. IFN priming is necessary but not sufficient to turn on a migratory dendritic cell program in lupus monocytes. J. Immunol. 192, 5586\u20135598 (2014).","journal-title":"J. Immunol."},{"key":"60937_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-023-01152-8","author":"CL Dai","year":"2023","unstructured":"Dai, C. L., Yang, H. X., Liu, Q. P., Rahman, K. & Zhang, H. CXCL6: a potential therapeutic target for inflammation and cancer. Clin. Exp. Med. https:\/\/doi.org\/10.1007\/s10238-023-01152-8 (2023).","journal-title":"Clin. Exp. Med."},{"key":"60937_CR24","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3389\/fphar.2019.00224","volume":"10","author":"MY Sun","year":"2019","unstructured":"Sun, M. Y. et al. CXCL6 Promotes renal interstitial fibrosis in diabetic nephropathy by activating JAK\/STAT3 signaling pathway. Front. Pharmacol. 10, 224 (2019).","journal-title":"Front. Pharmacol."},{"key":"60937_CR25","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1002\/1096-9896(200108)194:4<397::AID-PATH899>3.0.CO;2-S","volume":"194","author":"J Flier","year":"2001","unstructured":"Flier, J. et al. Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation. J. Pathol. 194, 398\u2013405 (2001).","journal-title":"J. Pathol."},{"key":"60937_CR26","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1002\/path.1721","volume":"205","author":"J Wenzel","year":"2005","unstructured":"Wenzel, J. et al. Enhanced type I interferon signalling promotes Th1-biased inflammation in cutaneous lupus erythematosus. J. Pathol.: J. Pathol. Soc. Great Br. Irel. 205, 435\u2013442 (2005).","journal-title":"J. Pathol.: J. Pathol. Soc. Great Br. Irel."},{"key":"60937_CR27","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.cyto.2015.01.031","volume":"73","author":"ES Robinson","year":"2015","unstructured":"Robinson, E. S. & Werth, V. P. The role of cytokines in the pathogenesis of cutaneous lupus erythematosus. Cytokine 73, 326\u2013334 (2015).","journal-title":"Cytokine"},{"key":"60937_CR28","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1002\/art.21034","volume":"52","author":"S Meller","year":"2005","unstructured":"Meller, S. et al. Ultraviolet radiation\u2013induced injury, chemokines, and leukocyte recruitment: an amplification cycle triggering cutaneous lupus erythematosus. Arthr. Rhuem. 52, 1504\u20131516 (2005).","journal-title":"Arthr. Rhuem."},{"key":"60937_CR29","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1016\/j.jid.2017.03.018","volume":"137","author":"B Scholtissek","year":"2017","unstructured":"Scholtissek, B. et al. Immunostimulatory endogenous nucleic acids drive the lesional inflammation in cutaneous lupus erythematosus. J. Invest. Dermatol. 137, 1484\u20131492 (2017).","journal-title":"J. Invest. Dermatol."},{"key":"60937_CR30","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/j.1600-065X.2009.00768.x","volume":"229","author":"KH Yi","year":"2009","unstructured":"Yi, K. H. & Chen, L. Fine tuning the immune response through B7-H3 and B7-H4. Immunol. Rev. 229, 145\u2013151 (2009).","journal-title":"Immunol. Rev."},{"key":"60937_CR31","first-page":"66","volume":"6","author":"JR Castellanos","year":"2017","unstructured":"Castellanos, J. R. et al. B7-H3 role in the immune landscape of cancer. Am. J. Clin. Exp. Immunol. 6, 66\u201375 (2017).","journal-title":"Am. J. Clin. Exp. Immunol."},{"key":"60937_CR32","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/ni967","volume":"4","author":"WK Suh","year":"2003","unstructured":"Suh, W. K. et al. The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. Nat. Immunol. 4, 899\u2013906 (2003).","journal-title":"Nat. Immunol."},{"key":"60937_CR33","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41416-022-02028-6","volume":"128","author":"G Piro","year":"2022","unstructured":"Piro, G. et al. CXCR1\/2 dual-inhibitor ladarixin reduces tumour burden and promotes immunotherapy response in pancreatic cancer. Br. J. Cancer. 128, 331\u2013341 (2022).","journal-title":"Br. J. Cancer"},{"key":"60937_CR34","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s12026-021-09177-5","volume":"69","author":"Y Chen","year":"2021","unstructured":"Chen, Y., Su, Z. & Liu, F. Effects of functionally diverse calpain system on immune cells. Immunol. Res. 69, 8\u201317 (2021).","journal-title":"Immunol. Res."},{"key":"60937_CR35","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.chembiol.2025.03.002","volume":"32","author":"N Horbach","year":"2025","unstructured":"Horbach, N. et al. Visualization of calpain-1 activation during cell death and its role in GSDMD cleavage using chemical probes. Cell. Chem. Biol. 32, 603\u2013619e7 (2025).","journal-title":"Cell. Chem. Biol."},{"key":"60937_CR36","first-page":"2804","volume":"15","author":"M Salinas-Santander","year":"2018","unstructured":"Salinas-Santander, M. et al. CAPN3, DCT, MLANA and TYRP1 are overexpressed in skin of vitiligo vulgaris Mexican patients. Exp. Ther. Med. 15, 2804\u20132811 (2018).","journal-title":"Exp. Ther. Med."},{"key":"60937_CR37","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/art.42391","volume":"75","author":"E Morand","year":"2023","unstructured":"Morand, E. et al. Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase II, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 75, 242\u2013252 (2023).","journal-title":"Arthritis Rheumatol."},{"key":"60937_CR38","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jdcr.2023.07.030","volume":"39","author":"N Bouch\u00e9","year":"2023","unstructured":"Bouch\u00e9, N., Al-Saedy, M. A. & Song, E. J. Successful treatment of refractory subacute cutaneous lupus erythematosus with deucravacitinib. JAAD Case Rep. 39, 93\u201395 (2023).","journal-title":"JAAD Case Rep."},{"key":"60937_CR39","doi-asserted-by":"crossref","unstructured":"Jiang, Y. et al. Cytokinocytes: the diverse contribution of keratinocytes to immune responses in skin. JCI Insight 5, 252 (2020).","DOI":"10.1172\/jci.insight.142067"},{"key":"60937_CR40","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.immuni.2020.03.001","volume":"52","author":"\u00c1 Teijeira","year":"2020","unstructured":"Teijeira, \u00c1. et al. CXCR1 and CXCR2 chemokine receptor agonists produced by tumors induce neutrophil extracellular traps that interfere with immune cytotoxicity. Immunity 52, 856\u2013871e8 (2020).","journal-title":"Immunity"},{"key":"60937_CR41","doi-asserted-by":"publisher","first-page":"3881","DOI":"10.1182\/blood-2006-08-044669","volume":"109","author":"OJ Florey","year":"2007","unstructured":"Florey, O. J., Johns, M., Esho, O. O., Mason, J. C. & Haskard, D. O. Antiendothelial cell antibodies mediate enhanced leukocyte adhesion to cytokine-activated endothelial cells through a novel mechanism requiring cooperation between Fc\u03b3RIIa and CXCR1\/2. Blood 109, 3881\u20133889 (2007).","journal-title":"Blood"},{"key":"60937_CR42","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1038\/s41588-026-02552-8","volume":"58","author":"P Restrepo","year":"2026","unstructured":"Restrepo, P. et al. Single-cell spatial transcriptomic analysis of human skin anatomy. Nat. Genet. 58, 903\u2013915 (2026).","journal-title":"Nat. Genet."},{"key":"60937_CR43","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/nrmicro2537","volume":"9","author":"EA Grice","year":"2011","unstructured":"Grice, E. A. & Segre, J. A. The skin microbiome. Nat. Rev. Microbiol. 9, 244\u2013253 (2011).","journal-title":"Nat. Rev. Microbiol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-60937-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-60937-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-60937-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:50:44Z","timestamp":1789473044000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-60937-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["60937"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-60937-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"assertion":[{"value":"17 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JMR is an inventor on patent application #63\/478,900 \u201cDiagnosis of skin diseases in veterinary and human patients\u201d for CTCL. JEH & JMR are inventors on patent application #62489191, \u201cDiagnosis and Treatment of Vitiligo\u201d which covers targeting IL-15 and Trm for the treatment of vitiligo; and on patent application #15\/851,651, \u201cAnti-human CXCR3 antibodies for the Treatment of Vitiligo\u201d which covers targeting CXCR3 for the treatment of vitiligo. JEH holds equity in Rheos Medicines and TeVido BioDevices; is a founder with equity of Villaris Therapeutics, Aldena Therapeutics, NIRA Biosciences, Vimela Therapeutics, and Klirna Therapeutics; has served as a consultant for Pfizer, Sanofi Genzyme, Incyte, Sun Pharmaceuticals, LEO Pharma, Dermavant, Temprian Therapeutics, AbbVie, Janssen, Almirall, Methuselah Health, Pandion, AnaptysBio, Avita, Aclaris Therapeutics, The Expert Institute, BiologicsMD, Boston Pharma, Sonoma Biotherapeutics, Two Biotech, Admirx, Frazier Management, 3rd Rock Ventrures, Gogen Therapeutics, Granular Therapeutics, Platelet Biogenesis, BridgeBio, Merck, Matchpoint Therapeutics, and Klirna; has served as an investigator for Pfizer, Sanofi Genzyme, Incyte, Sun Pharmaceuticals, LEO Pharma, Dermavant, Aclaris Therapeutics, GSK, Celgene, Dermira, and EMD Serono. LZ, ML & YL are employees of NanoString Technologies. MR is principal or co-investigator of studies sponsored by Pfizer, Biogen, AbbVie, Incyte, LEO Pharma, Abeona Therapeutics, Dermavant, and Target RWE; and MR provides consulting for Pfizer, Biogen, Incyte, Takeda, Inzen, ROME Therapeutics, Almirall, Medicxi, Related Sciences, and VisualDx. Remaining authors declare that they have no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This study was performed with internal review board (IRB) approved protocols at the UMass Chan Medical School (H-14848 and H00021295 for fresh blood and skin tissue; H00020503 for archival skin tissue), Yale University Institutional Review Board (Human Investigative Committee no. 15010105235 for archival skin tissue), and\/or Dartmouth Hitchcock Medical Center (STUDY02001542 for PBMCs), and all samples were obtained with written informed consent and were de-identified before use in experiments.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"28736"}}